The FDA last week approved Novo Nordisk’s Rybelsus, a once-daily oral Type 2 diabetes drug that some analysts are already calling a ‘holy grail’ treatment. The new therapy will compete directly with Boehringer Ingelheim’s Jardiance, which holds preferred status for 50% of covered lives, and Merck’s Januvia, which holds preferred status for 58% of covered lives.

SOURCE: MMIT Analytics, as of 9/25/19